<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317965</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-100</org_study_id>
    <nct_id>NCT02317965</nct_id>
  </id_info>
  <brief_title>Non-Invasive Screening for Fetal Aneuploidy</brief_title>
  <official_title>A Prospective Clinical Study to Evaluate a Novel Non-invasive Prenatal Screening Method for Characterizing Fetal Whole Chromosome Aberrations and Other Major Defects and Deletions Found in the Maternal Blood.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Progenity, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Obstetrix Medical Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Progenity, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to detect whole chromosome abnormalities in maternal blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to detect whole chromosome abnormalities on all chromosomes 13,&#xD;
      16, 18, 21, X and Y, in the fetus through analysis of cell free and compound sample DNA (cf&#xD;
      DNA and cs DNA, respectively) in maternal blood. In addition, major deletions and&#xD;
      duplications in chromosomes 1, 4, 5, and 22 will be detected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validate the prenatal aneuploidy laboratory developed test (LDT) with maternal blood samples from pregnant women who are undergoing invasive prenatal diagnosis</measure>
    <time_frame>Participants will have a single visit and completion in study occurs once invasive procedure results have been recorded.</time_frame>
    <description>A single 20 mL blood sample will be obtained from each subject during the first or second trimester, blind-coded, and transferred to the Sponsor Laboratory for processing to plasma.&#xD;
Subjects electing to undergo an invasive procedure for fetal Karyotyping (defined as standard cytogenetics and/or microarray, FISH, QF-PCR) will have the blood sample obtained prior to the procedure.&#xD;
The performance characteristics (sensitivity, specificity, negative and positive predictive value) of the laboratory developed test to detect whole chromosome abnormalities on all chromosomes 13, 16, 18, 21, X and Y will be determined using fetal karyotype on specimens obtained by chorionic villus sampling and/or genetic amniocentesis for those subjects who undergo these diagnostic procedures as part of their standard care as the gold standard.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Edwards Syndrome</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <description>Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure&#xD;
Intervention: Single Maternal blood draw of 20mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maternal Blood Draw</intervention_name>
    <description>Maternal Blood Draw</description>
    <arm_group_label>Pregnant Women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, PBMCs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will&#xD;
        receive the fetal FISH and/or karyotype results from the procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â€¢ Subject is a pregnant woman 18-54 years of age at 8-22 weeks' gestation inclusive;&#xD;
&#xD;
               -  Subject has additional risk indicators for fetal chromosome aneuploidy, including&#xD;
                  one or more of the following:&#xD;
&#xD;
               -  Maternal age &gt; 34 years at the estimated date of delivery;&#xD;
&#xD;
               -  Positive serum screening test suggesting fetal aneuploidy;&#xD;
&#xD;
               -  Previous positive noninvasive cfDNA test is acceptable&#xD;
&#xD;
               -  Fetal ultrasound abnormality suggesting fetal chromosomal abnormality;&#xD;
&#xD;
               -  Personal or family history of Down syndrome or other chromosomal aneuploidy.&#xD;
&#xD;
               -  Willing to provide written informed consent&#xD;
&#xD;
               -  Willing to be re-contacted subsequently for additional information and/or testing&#xD;
                  if necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will not be entered into this study if they meet the following criteria:&#xD;
&#xD;
               -  Fetal demise at the time of the blood draw;&#xD;
&#xD;
               -  Previous specimen donation under this protocol;&#xD;
&#xD;
               -  Unwilling or lacks the capacity to provide informed consent or to comply with&#xD;
                  study procedures;&#xD;
&#xD;
               -  Currently under treatment for cancer&#xD;
&#xD;
               -  Any history of autoimmune disease&#xD;
&#xD;
               -  Any pelvic mass&#xD;
&#xD;
               -  Previous history of radiation to pelvis&#xD;
&#xD;
               -  Any history or current evidence of a twin demise at any gestational age.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Porreco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrix Medical Group of Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Garite, MD</last_name>
    <role>Study Director</role>
    <affiliation>Obstetrix Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obstetrix Medical Group of California</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Ctr - 2nd Floor Perinatal</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OBX Med. Group. of Colorado - Pres/St Luke's Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OBX Med. Group. of Colorado - Antepartum Testing Unit @ Rose Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OBX Med. Group. of Colorado - Perinatal Resource Ctr @ Swedish Med Ctr.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OBX Med. Group. of Colorado - Skyridge</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Obstetrical Consultants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrix Medical Group of Texas</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrix Medical Group of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrix, Medical Group of Washington, Inc. - Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Trisomy 18 Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

